About US
Contact us
-
Sobi seeks European approval of Xiapex for Peyronies diseaseSwedish Orphan Biovitrum (Sobi) has filed for an extension of the label for Xiapex (collagenase clostridium histolyticum) with the European Medicines Agency to include the indication of Peyronie's dis2014/6/30
-
FDA grants orphan drug designation to Insys Therapeutics’ pharmaceutical cannabidiolUS-based specialty pharmaceutical company Insys Therapeutics has obtained orphan drug designation from the US Food and Drug Administration (FDA) for its pharmaceutical cannabidiol for treatment of Len2014/6/30
-
Ligand Pharma and TG Therapeutics sign licence agreement for IRAK-4 inhibitor programmeUS-based Ligand Pharmaceuticals has signed an exclusive global licence agreement with TG Therapeutics to develop and commercialise Ligand's interleukin-1 receptor associated kinase-4 (IRAK-4) inhibito2014/6/27
-
Mersana and Merck to develop antibody-drug conjugatesMersana Therapeutics has signed an agreement with EMD Serono, Merck's biopharmaceutical division, to co-develop next-generation antibody-drug conjugates (ADCs). Mersana's Fleximer technology will be2014/6/27
-
The Fourth PhExFEST & International Pharmaceutical Preparations and Pharmaceutical Excipients Development Forum has been successfully concludedThe 4th PhExFEST & 2014 International Pharmaceutical Preparations and Pharmaceutical Excipients Development Forum held in Jinan Wanda Hyatt Hotel successfully On June 19-22, 2014! The PhExFEST att2014/6/26
-
Abbott to acquire Russian pharmaceutical companyUS-based healthcare company Abbott has entered into a definitive agreement to acquire Veropharm, a Russia-based pharmaceutical firm. Under the agreement, Abbott will acquire Garden Hills, which curre2014/6/26
-
Bayer’s Nexavar receives Japanese approvalBayer HealthCare has obtained approval from the Japanese Ministry of Health, Labour and Welfare (MHLW) for its Nexavar (sorafenib) for treatment of patients with unresectable differentiated thyroid ca2014/6/26
-
Celsion completes acquisition of EGENCelsion has completed the acquisition of EGEN, including its Phase Ib product candidate EGEN-001 and therapeutic platform technologies, TheraPlas, TheraSilence, and RAST. Under the terms of the agree2014/6/25
-
FDA accepts Cubist’s new drug application for ceftolozane/tazobactam with priority reviewCubist Pharmaceuticals' new drug application for its ceftolozane/tazobactam for treatment of complicated urinary tract infections and complicated intra-abdominal infections has been accepted by the US2014/6/25
-
CDC says 75 Atlanta-based staff possibly exposed to anthraxThe Centers for Disease Control and Prevention (CDC) has reported that 75 Atlanta-based staff may have been unintentionally exposed to live Bacillus anthracis, the cause of the anthrax disease, and ar2014/6/24